Related Experiment Video

Updated: May 17, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

MicroRNA involvement in gastrointestinal stromal tumor tumorigenesis

Won Kyu Kim1, Han-Kwang Yang, Hoguen Kim

  • 1Brain Korea 21 Projects for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Current Pharmaceutical Design
|October 25, 2012
PubMed

Insights

Gastrointestinal stromal tumors (GIST) often involve KIT or PDGFRA mutations. MicroRNAs show potential for GIST treatment, offering new therapeutic avenues beyond imatinib for resistant cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal mesenchymal tumor.
  • GIST pathogenesis is well-characterized, involving activating mutations in c-Kit-kinase (KIT) or platelet-derived growth factor receptor A (PDGFRA).
  • Imatinib, a KIT inhibitor, is a standard treatment, but resistance, particularly with KIT exon 13 or 17 mutations, necessitates alternative therapies.

Purpose of the Study:

  • To review GIST characteristics, molecular mechanisms, and clinical implications.
  • To explore the role of microRNAs in GIST development and progression.
  • To discuss the potential of microRNAs as therapeutic targets for GIST.

Main Methods:

  • Literature review of GIST pathogenesis, molecular alterations, and therapeutic strategies.
  • Analysis of studies investigating microRNA involvement in GIST.
  • Synthesis of current knowledge on microRNA regulation of KIT and GIST cell proliferation.

Main Results:

  • Activating mutations in KIT (80%) and PDGFRA (35%) drive GIST formation and signaling pathway activation.
  • Imatinib resistance occurs in some GISTs, highlighting the need for novel treatments.
  • MicroRNAs are dysregulated in cancers and can directly regulate KIT expression, inhibiting GIST cell proliferation.

Conclusions:

  • GISTs are driven by specific kinase mutations, with imatinib resistance posing a clinical challenge.
  • MicroRNAs play a significant role in GIST tumorigenesis by regulating key oncogenes like KIT.
  • MicroRNAs represent a promising therapeutic strategy for GIST, potentially overcoming imatinib resistance.

More Related Videos

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts10:33

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts

Published on: April 29, 2014

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...